UroAlerts - Prostate Cancer Weekly

June 23, 2026

Videos

Peer-to-Peer Clinical Conversations

Scaling Operations in Theranostics Clinical Research: Integrating Teams, Processes, and Regulatory Strategy "Presentation" - Stephanie Lira

At the 2026 UCSF-UCLA PSMA Conference, Stephanie Lara describes how UCLA's theranostics clinical trials program scaled from 11 studies and 10 staff in 2019 to over 60 trials.

Phase 1 Study Evaluates Bone Metastasis Resolution with SYNC-T Therapy SV-102 - Gerald Andriole

Gerald Andriole

Zachary Klaassen hosts Gerald Andriole to discuss SYNC-T therapy SV-102 for metastatic prostate cancer.

Beyond the Abstracts

Aglatimagene Besadenovec (CAN-2409) with Radiotherapy for Patients with Localised Prostate Cancer: A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial - Beyond the Abstract

Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation - Beyond the Abstract

Conference Coverage

ASCO 2026: Optimizing Care for Patients with mCRPC: Integration of Palliative Care in Metastatic Prostate Cancer – Reflection and Advocacy

ASCO 2026: CONVERGE-01 Part 3: Ac-225 Rosopatamab Tetraxetan (CONV01-α) in 177Lu-PSMA-617 Pretreated mCRPC

SNMMI 2026: Olaparib Sensitizes Prostate Cancer to 177Lu-PSMA-617 Radioligand Therapy via Suppression of Glycolysis

AUA 2026: Radiographic Progression-free Survival as a Meaningful Endpoint in Metastatic Castration-Resistant Prostate Cancer (mCRPC): The TALAPRO-2 Randomized Clinical Trial

AUA 2026: Real-World Darolutamide Safety and Effectiveness in Patients with Nonmetastatic Castration-Resistant Prostate Cancer with Comorbidities and Concomitant Medications: Post Hoc Analyses at DAROL Interim Analysis 4 (IA4)

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Same Target, Different Tools: A Multicenter Comparison of Clinically Significant Prostate Cancer Detection Across Three MRI-Targeted Transperineal Biopsy Techniques

Current state of the art of new prostate MRI technologies and potential future developments.

Investigation of Potential Splenic Metastasis on Prostate-Specific Membrane Antigen (PSMA) Imaging in High-Risk Prostate Cancer: A Role for MRI?

Surgical Complications in a large series of Retzius-sparing robot-assisted radical prostatectomy: impact of surgical experience and technical modifications (1016 cases).

Direct Androgen Receptor Antagonism Enhances Therapeutic PSMA Radioligand Uptake in Prostate Cancer Models.

Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.

A Histopathologic Assessment of Prostate Ductal Anatomy in Relation to Micro-Ultrasound.

Associations of testosterone, sex hormone-binding globulin, and related hormones with risks of cancer death, incident cancer, and incident prostate cancer in men: individual participant data meta-analyses.

Mortality in Castration Resistant Prostate Cancer Patients With and Without Pre-Existing Cardiovascular Disease Receiving Oral Androgen Receptor Pathway Inhibitors.

Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.

Prostate Cancer Working Group 4 Recap.

Association of asymptomatic PSA testing on prostate cancer mortality; a case control study in general practice.

Standardizing PSMA PET/CT reporting in prostate cancer: from structured frameworks to AI-assisted interpretation.

Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.

Long-term Outcomes in Men with Stable PSA During 5-α Reductase Inhibitor Therapy After Negative Prostate Biopsy: Population-based Study.

Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer: A Nonrandomized Clinical Trial.

Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.

CDK4-selective inhibitor AU2-94 for the treatment of advanced and therapy-resistant prostate cancer.

AI-Assisted Prostate Cancer Diagnosis Using Biparametric MRI and PI-RADS v2.1: Performance Comparison Between Novice-Level and Experienced Readers.

Piggybacking Towards Progress for CAR-T Cell Therapy in Prostate Cancer.

The Landscape of Prostate Tumour Methylation.

Prostate Cancer Mortality Among Men with and Without Comorbidity: Long-Term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam - Beyond the Abstract

Single-port robotic radical prostatectomy: early results from a UK centre.

Integrative Oncology for Prostate Cancer: A Narrative Review.

3D Genome Architecture and Epigenetic Regulation of Lineage Identity in Advanced Prostate Cancer.

Targeted Prostate Health Checks for prostate cancer in men at high risk: a feasibility pilot in primary and secondary care in North East London.

Concomitant MRI-detected and MRI-undetected Prostate Cancer with Implications for Biopsy Strategies and Focal Therapy Planning: An Analysis of the PROMIS and PICTURE Trials.

Development and validation of a digital pathology artificial intelligence (DPAI)-derived risk score predicting Gleason grade group reclassification for patients who are candidates for active surveillance.

New Swedish Biopsy Needle Receives FDA Approval – Secures SEK 17 Million in Capital

da Vinci® single-port versus da Vinci® Xi multiport robot-assisted radical prostatectomy for localized prostate cancer: a GRADE-assessed systematic review and meta-analysis.

Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy.

Limitations in diagnostics and quantification of small lesions with low uptake in the clinical context of prostate 18F/68Ga-PSMA PET/MRI.

International Delphi consensus on single-port robotic radical prostatectomy: patient selection, surgical technique, and training.

Bayesian re-analysis of ERA223 and PEACE-3 temporal dynamics and bone protection in radium-223-treated metastatic castration-resistant prostate cancer.

NeuroSAFE-Guided Robot-Assisted Radical Prostatectomy versus Standard RARP: Systematic Review and Meta-Analysis of Comparative Studies - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC